Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
29th Annual Credit Suisse Virtual Healthcare Conference
Presentation Date: Monday, November 9th at 5 p.m. Eastern Time
-
Barclays Gene Editing & Gene Therapy Summit
Presentation Date: Monday, November 16th at 10:45 a.m. Eastern Time
Presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo website after the event.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005222/en/
Sangamo Therapeutics Inc. Stock
Based on 11 Buy predictions and 13 Sell predictions the sentiment towards Sangamo Therapeutics Inc. is rather balanced.
On the other hand, the target price of 2 € is above the current price of 0.51 € for Sangamo Therapeutics Inc., so the potential is actually 289.64%.
